Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers

Virchows Archiv

Volumn 465, Issue 3, 2014, Pages 365-369

  Gevensleben, Heidrun ^a   Bossung, Verena ^b,c   Meindl, Alfons ^d   Wappenschmidt, Barbara ^b   de Gregorio, Nikolaus ^e   Osorio, Ana ^f   Romero, Atocha ^g   Buettner, Reinhard ^b   Markiefka, Birgid ^b   Schmutzler, Rita Katharina ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f Centro Nacional de Investigations Oncológicas   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; RAD51C PROTEIN, HUMAN;

BREAST TUMOR; FEMALE; GENETICS; GERMLINE MUTATION; HETEROZYGOTE; HUMAN; LETTER; MUTATION; OVARY TUMOR; PATHOLOGY; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; MUTATION; OVARIAN NEOPLASMS;

EID: 84908181346     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-014-1619-1     Document Type: Letter

References (6)

1. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, Ramser J, Honisch E, Kubisch C, Wichmann HE, Kast K, Deissler H, Engel C, Muller-Myhsok B, Neveling K, Kiechle M, Mathew CG, Schindler D, Schmutzler RK, Hanenberg H (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42(5):410–414. doi:10.1038/ng.569
2. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, Rodriguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Sanchez L, Rivas C, Benitez J (2003) Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 9(10 Pt 1):3606–3614
3. Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, Blomqvist C, Aittomaki K, Butzow R, Nevanlinna H (2011) RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet 20(16):3278–3288. doi:10.1093/hmg/ddr229
4. Cunningham JM, Cicek MS, Larson NB, Davila J, Wang C, Larson MC, Song H, Dicks EM, Harrington P, Wick M, Winterhoff BJ, Hamidi H, Konecny GE, Chien J, Bibikova M, Fan JB, Kalli KR, Lindor NM, Fridley BL, Pharoah PP, Goode EL (2014) Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Sci Rep 4:4026. doi:10.1038/srep04026
5. Ozretic L, Rhiem K, Huss S, Wappenschmidt B, Markiefka B, Sinn P, Schmutzler RK, Buettner R (2011) High nuclear poly(adenosine diphosphate-ribose) polymerase expression is predictive for BRCA1- and BRCA2-deficient breast cancer. J Clin Oncol 29(34):4586–4588. doi:10.1200/JCO.2011.38.1988, author reply 4588
6. Schnurbein G, Hauke J, Wappenschmidt B, Weber-Lassalle N, Engert S, Hellebrand H, Garbes L, Becker A, Neidhardt G, Rhiem K, Meindl A, Schmutzler RK, Hahnen E (2013) RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families. Breast Cancer Res 15(6):R120. doi:10.1186/bcr3589